Skip to content

Ketamine for depression: all studies

Page 158 of 173: studies 1,571 to 1,580 of 1,728, newest first. Back to the ketamine for depression overview

Research

Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression

Psychotherapy and Psychosomatics 2017 Samuel T. Wilkinson, Dashaun Wright, Madonna K. Fasula et al. 120 citations

<b><i>Introduction:</i></b> Ketamine has shown rapid though short-lived antidepressant effects. The possibility of concerning neurobiological changes following repeated exposure to the drug motivates the development of strategies that obviate or minimize the need for longer-term treatment with ketamine. In this open-label trial, we investigated whether cognitive behavioral therapy (CBT) can...

Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder

The Journal of Clinical Psychiatry December 6, 2016 Jennifer L. Vande Voort, Elizabeth D. Ballard, David A. Luckenbaugh et al. 67 citations

OBJECTIVE: Insomnia and disrupted sleep are associated with increased risk of suicide. The N-methyl-d-aspartate antagonist ketamine has been associated with reduced suicidal thoughts, but the mechanism of action is unknown. This study sought to evaluate differences in nocturnal wakefulness in depressed individuals who did and did not have an antisuicidal response to ketamine. METHODS:...

Continuation phase intravenous ketamine in adults with treatment-resistant depression.

Journal of Affective Disorders December 2016 Jennifer L. Vande Voort, Robert J Morgan, Simon Kung et al.

Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5mg/kg, administered...

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Neuroscience Bulletin December 2016 Weili Zhu, Zengbo Ding, Yinan Zhang et al.

Major depression is a serious psychiatric disorder and remains a leading cause of disability worldwide. Conventional antidepressants take at least several weeks to achieve a therapeutic response and this lag period has hindered their ability to attain beneficial effects in depressed individuals at high risk of suicide. The non-competitive N-methyl-D-aspartate glutamate receptor antagonist...

[Ketamine administration in case of severe, therapy resistant depressed patient, case report].

Ideggyogyaszati szemle November 30, 2016 Szabolcs Morvai, Attila István Nagy, Adrienn Bálint-Szöllősi et al.

Objective - In our case report we present the treatment of a female patient suffering from therapy resistant depression. This procedure is not in practice in Hungary at present, the aim of our work to reproduce the findigs of international studies in domestic circumstances. Matter - Major depression is a common, chronic and severe mental disorder, with 16.2% lifetime prevalence. Many...

Continuous Social Defeat Induces Depression-Like Symptoms Including Anhedonia and Slowed Time Perception that are Rapidly Reversed by Ketamine

Timing &amp; Time Perception November 26, 2016 Bin Yin, Sven Thönes, Ruey-Kuang Cheng et al.

Male Sprague–Dawley rats were exposed to social defeat and subordination by aggressive male Long–Evans rats. The social defeat procedure involved the continuous exposure to an aggressive resident for 10 days, while living in a protective cage within the resident’s home cage with daily brief confrontations. These stress experiences resulted in 1) reduced body weight; 2) decreased social...

S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression

The International Journal of Neuropsychopharmacology November 2, 2016 Maryam Ardalan, Gregers Wegener, Ali H. Rafati et al. 38 citations

Background: The neurovascular plasticity of hippocampus is an important theory underlying major depression. Ketamine as a novel glutamatergic antidepressant drug can induce a rapid antidepressant effect within hours. In a mechanistic proof of this concept, we examined whether ketamine leads to an increase in synaptogenesis and vascularization within 24 hours after a single injection in a...

Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.

Drug Development Research November 2016 Vesna Pešić, Jelena Petrović, Marin M Jukić

Preclinical Research The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of...

Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression.

Hippocampus November 2016 Maryam Ardalan, Gregers Wegener, Benedetta Polsinelli et al.

Glutamatergic system and the structural plasticity hypothesis are principal components for rapid and sustained antidepressant effects of novel antidepressant therapeutics. This study represents the first investigation of the structural plasticity of the hippocampus as one of the main contributed mechanisms to the sustained anti-depressive effect of ketamine. Flinders Sensitive Line (FSL) and...